SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-22-048046
Filing Date
2022-08-15
Accepted
2022-08-15 16:17:45
Documents
41
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT f10q0622_ayalapharma.htm   iXBRL 10-Q 435877
2 AMENDMENT NO. 2 TO AMENDED AND RESTATED INVESTORS' RIGHTS AGREEMENT, DATED AS OF f10q0622ex4-1_ayalapharma.htm EX-4.1 24394
3 CERTIFICATION f10q0622ex31-1_ayalapharma.htm EX-31.1 9267
4 CERTIFICATION f10q0622ex31-2_ayalapharma.htm EX-31.2 9540
5 CERTIFICATION f10q0622ex32-1_ayalapharma.htm EX-32.1 3899
6 CERTIFICATION f10q0622ex32-2_ayalapharma.htm EX-32.2 4121
  Complete submission text file 0001213900-22-048046.txt   2246196

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE ayla-20220630.xsd EX-101.SCH 25099
8 XBRL CALCULATION FILE ayla-20220630_cal.xml EX-101.CAL 20893
9 XBRL DEFINITION FILE ayla-20220630_def.xml EX-101.DEF 108049
10 XBRL LABEL FILE ayla-20220630_lab.xml EX-101.LAB 222215
11 XBRL PRESENTATION FILE ayla-20220630_pre.xml EX-101.PRE 112356
35 EXTRACTED XBRL INSTANCE DOCUMENT f10q0622_ayalapharma_htm.xml XML 161817
Mailing Address 1313 N. MARKET STREET SUITE 5100 WILMINGTON DE 19801
Business Address 1313 N. MARKET STREET SUITE 5100 WILMINGTON DE 19801 (857) 444-0553
Ayala Pharmaceuticals, Inc. (Filer) CIK: 0001797336 (see all company filings)

IRS No.: 823578375 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39279 | Film No.: 221165853
SIC: 2836 Biological Products, (No Diagnostic Substances)